Jerusalem, Israel

Time filter

Source Type

News Article | May 9, 2017
Site: www.prnewswire.com

JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent...


News Article | May 18, 2017
Site: www.prnewswire.com

JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that  Chief Executive Officer, Nadav Kidron, will present at three conferen...


— Market Scenario: Human insulin is also known as synthetic insulin which is prepared in laboratory and has same characteristics like natural insulin. Human insulin was developed through the 1960s and 1970s and approved for pharmaceutical use in 1982. Before the invention of human insulin animal insulin, usually a purified form of porcine was used. The market for global human insulin is expected to reach up to $40 billion by the end of the forecasted period and is expected to grow at a CAGR of ~10-12%. The major factors contributing to the market growth are; increase in prevalence of diabetic population, rise in geriatric population, rising awareness of diabetes and rising prevalence of obesity. “Ask for your specific company profile and country level customization on reports” Key Players Adocia (France.) Merck & Co. (U.S.) Julphar (UAE) Bristol-Myers Squibb Company (U.S.) GlaxoSmithKline Plc (U.K.) Biocon Ltd. (India) Tonghua Dongbao Pharmaceuticals Co., Ltd. (China) Oramed Pharmaceuticals, Inc. (Israel) Novo Nordisk A/S (Denmark) However, strict regulatory requirements for approval of insulin and high cost of analog are inhibiting the growth of the global human insulin market. Along with that, delayed onset of action, and various side effects of human insulin are also limiting the growth of this market across the globe. Key Findings • Increasing prevalence of diabetic population, rising prevalence of obesity, and rise in geriatric population are major factors driving the growth of the human insulin market • Strict regulatory requirements for approval of insulin and high cost of insulin analog inhibits the growth of the Human Insulin Market • Geographically, North America has the largest share in global human insulin market, while Asia-Pacific has emerged as the fastest growing region • Based on the type, modern human insulin has the largest market share in the human insulin market Taste the market data and market information presented through more than 85 market data tables and figures spread in 180 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global human insulin Market Information- Global Forecast to 2021" Regional Analysis of Human Insulin Market Globally North America is the largest market for human insulin, large share of this market is attributed to growing prevalence of diabetes and obesity. The North American market for human insulin is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Europe is the second-largest market for human insulin, which is expected to grow at a CAGR of XX% Table of Content 1. Report Prologue 2. Introduction 2.1 Definition 2.2 Scope of the Study 2.2.1 Research Objective 2.2.2 Assumptions 2.2.3 Limitations 2.3 Market Structure 2.4. Market Segmentation 3. Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 3.4 Market Size Estimation 3.5 Forecast Model 4. Market Dynamics 4.1 Drivers 4.2 Restraints 4.3 Opportunities 4.4 Mega Trends 4.5 Macroeconomic Indicators 4.6 Important Pointers By Industry Experts 4.6.1 Fastest Growing Market 4.6.2 Growth Prospects 4.7 Regulations/Acts 5. Market Factor Analysis 5.1 Value Chain Analysis 5.2 Porters 6. Human Insulin Market 2016-2020: By Types (Us $ Million) 6.1 Introduction 6.2 Historic Market Growth 6.3 Market Size (Sub Segments) 6.3.1 Traditional Human Insulin 6.3.1.1 Short Acting Human Insulin 6.3.1.2 Intermediate Acting Human Insulin 6.3.2 Modern Human Insulin 6.3.2.1 Long Acting Human Insulin 6.3.2.2 Rapid Acting Human Insulin 6.3.2.3 Premixed Human Insulin 7. Human Insulin Market, By Region Market Value & Volume Forecast (Us $ Million) 7.1 Introduction 7.2 Market Size by Region 7.2.1 Americas 7.2.1.1 North America 7.2.1.1.1 US 7.2.1.1.2 Canada 7.2.1.2 Latin America 7.2.2 Europe 7.2.2.1 Western Europe 7.2.2.1.1 Germany 7.2.2.1.2 France 7.2.2.1.2 Italy 7.2.2.1.4 Spain 7.2.2.1.5 UK 7.2.2.1.6 Rest Of Western Europe 7.2.3.1 Eastern Europe 7.2.3 Asia-Pacific 7.2.3.1 China 7.2.3.2 India 7.2.3.3 Japan 7.2.3.4 Rest of Asia Pacific 7.2.4 Middle East & Africa 8. Company Landscape 8.1 Introduction 8.2 Product Launch/Development 8.3 Partnerships and Collaborations 8.4 Acquisitions 8.5 Business Expansion Continue………….. Get List of Tables & Figures with Sample Report @ https://www.marketresearchfuture.com/sample-request/global-human-insulin-market-information-from-2011-to-2021 Modern human insulin, also known as analog insulin, is prescribed by physicians for the treatment of diabetes. It is the customized form of traditional human insulin and provides effective results in comparison to traditional human insulin. This research report has provides the insights, on various levels of analyses such industry analysis, market share analysis leading market players and their profiles. This report also helps in studying the target segments by providing views on emerging & high-growth segments and market conclusion. Together the market data comprise and discuss with the basic assessments on the competitive scenarios & strategies, of the global human insulin market, including the high-growth regions, countries and their political, economic and technological environments. Furthermore the project report also provides the views over the historical market values as well as, pricing and cost analysis of the same. Related Report Global Astigmatism Market Information, by type (Myopic Astigmatism, Hyperopic Astigmatism and others), by treatment (Corrective Lenses, Orthokeratology (Ortho-K), Surgeries and others), by end user (Hospital, Clinics and others) - Forecast to 2022 https://www.marketresearchfuture.com/reports/astigmatism-market-research-report-global-forecast-to-2022 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. For more information, please visit https://www.marketresearchfuture.com/sample-request/global-human-insulin-market-information-from-2011-to-2021


News Article | November 16, 2016
Site: marketersmedia.com

— Segments: Segmentation for the global human insulin market comprises of the following types such as Traditional Human Insulin which comprises of • Short Acting Human Insulin, • Intermediate Acting Human Insulin, • Premixed Human Insulin. Modern Human Insulin which consists of • Long Acting Human Insulin, • Rapid Acting Human Insulin • Premixed Human Insulin Key Players for Human Insulin Market: Some of the key players for this market are: • Biocon Ltd(India), • Tonghua Dongbao Pharmaceuticals Co., Ltd., • ADOCIA, • Merck & Co, • Julphar, • Pfizer, Inc, • Bristol-Myers Squibb Company, • GlaxoSmithKline, • Oramed Pharmaceuticals, Inc, • Novo Nordisk A/S • Sanofi Market Scenario: Human insulin refers to synthetic insulin manufactured in laboratories by growing insulin protein with the help of E. coli bacteria. Previously, before human insulin was established as animal insulin, usually a purified form of porcine (pork) insulin was used. It is expected that the market for global human insulin market is expected to grow at a CAGR of 12.1% from 2016 – 2027. Regional Analysis of Human Insulin Market: North America is a prominent market for human insulin market and dominated the Global market share. It has been valued at $11,127.9 in 2015 million and is expected to grow over $XX million by 2027. The European human insulin market stands as second largest market which is expected to grow with a CAGR of 12.2% during the forecasted period. Asia Pacific has emerged as the fastest growing market which has been valued at US $6,298 million in 2015 and expected to reach US $XX million by the end of forecasted period with the CAGR of more than 13.2%. Table of Content 1. REPORT PROLOGUE 2. INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.2.1 RESEARCH OBJECTIVE 2.2.2 ASSUMPTIONS 2.2.3 LIMITATIONS 2.3 MARKET STRUCTURE 2.4. MARKET SEGMENTATION 3. RESEARCH METHODOLOGY 3.1 RESEARCH PROCESS 3.2 PRIMARY RESEARCH 3.3 SECONDARY RESEARCH 3.4 MARKET SIZE ESTIMATION 3.5 FORECAST MODEL 4. MARKET DYNAMICS 4.1 DRIVERS 4.2 RESTRAINTS 4.3 OPPORTUNITIES 4.4 MEGA TRENDS 4.5 MACROECONOMIC INDICATORS 4.6 IMPORTANT POINTERS BY INDUSTRY EXPERTS 4.6.1 FASTEST GROWING MARKET 4.6.2 GROWTH PROSPECTS 4.7 REGULATIONS/ACTS 5. MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.2 PORTERS 6. Human Insulin Market 2016-2020: BY types (US $ MILLION) 6.1 INTRODUCTION 6.2 HISTORIC MARKET GROWTH 6.3 MARKET SIZE (SUB SEGMENTS) 6.3.1 Traditional Human Insulin 6.3.2 Modern Human Insulin 7. Human Insulin Market, by Region Market Value & Volume Forecast (US $ MILLION) 7.1 INTRODUCTION 7.2 MARKET SIZE BY REGION 7.2.1 AMERICAS 7.2.1.1 NORTH AMERICA 7.2.1.1.1 US 7.2.1.1.2 CANADA 7.2.1.2 LATIN AMERICA 7.2.2 EUROPE 7.2.2.1 WESTERN EUROPE 7.2.2.1.1 GERMANY 7.2.2.1.2 FRANCE 7.2.2.1.2 Italy 7.2.2.1.4 Spain 7.2.2.1.5 UK 7.2.2.1.6 REST OF WESTERN EUROPE 7.2.3.1 EASTERN EUROPE 7.2.3 ASIA-PACIFIC 7.2.3.1 CHINA 7.2.3.2 INDIA 7.2.3.3 JAPAN 7.2.3.4 REST OF ASIA PACIFIC 7.2.4 MIDDLE EAST & AFRICA 8. COMPANY LANSCAPE 8.1 INTRODUCTION 8.2 PRODUCT LAUNCH/DEVELOPMENT 8.3 PARTNERSHIPS AND COLLABORATIONS 8.4 ACQUISITIONS 8.5 BUSINESS EXPANSION 9. COMPANY PROFILE Continued…….. Reasons to Purchase this report: From an insight perspective, this research report has focused on various levels of analyses—industry analysis (industry trends), market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high-growth segments of the Global Human Insulin Market, high-growth regions, and market drivers, restraints, and opportunities. Key questions answered in this report • What will the market size be in 2027 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? Related Report Keratoacanthoma Market Research Report- Global Forecast to 2022 The global market is expected to reach US$ XX by the end of the forecasted period and is expected to grow at a CAGR of XX%. Know more about this report @ https://www.marketresearchfuture.com/reports/keratoacanthoma-market-research-report-global-forecast-to-2022 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. For more information, please visit https://www.marketresearchfuture.com


Patent
Oramed Pharmaceuticals | Date: 2016-01-15

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.


Patent
Oramed Pharmaceuticals | Date: 2014-04-23

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.


News Article | August 4, 2015
Site: www.businesswire.com

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announces that the Company has appointed Michael Berelowitz, M.D. to its Board of Directors. With Dr. Berelowitz’ appointment, Kamada’s Board will have ten directors. Dr. Berelowitz brings over 40 years of clinical development and academic research experience, including 15 years of pharmaceutical development experience with Pfizer, Inc. While at Pfizer, Dr. Berelowitz was Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit. He held various other roles at Pfizer, beginning as a Medical Director in the Diabetes Clinical Research team and then assuming positions of increasing responsibility. Prior to that, Dr. Berelowitz spent a number of years in academia and has held appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at StonyBrook and, most recently, Mount Sinai School of Medicine. “It is with great pleasure that we welcome Dr. Berelowitz to our Board. His wide-ranging background, considerable industry experience, and deep insight into successful commercialization and clinical strategies will be extremely valuable to Kamada as we advance and expand our robust clinical development programs for our immunomodulatory plasma-derived protein therapeutics,” stated David Tsur, co-founder and Deputy Chairman of the Board of Kamada. “Specifically, Dr. Berelowitz’ extensive knowledge of the diabetes landscape will be a great asset for Kamada as we advance our AAT to treat type-1 diabetes.” In accepting this appointment, Dr. Berelowitz stated, “I am excited to join Kamada at this important stage in its development. I believe that Kamada’s AAT has considerable potential to modulate or to prevent immune reactions, which could translate to broad therapeutic potential. I am particularly excited about the opportunity for Kamada’s AAT as a treatment for newly-diagnosed type-1 diabetes as it may be able to preserve beta cells, which could slow disease progression, improve metabolic control, and most importantly, reduce the complications of this debilitating disease. I look forward to working with my fellow Kamada Board members and the management team to help the Company achieve its strategic objectives, as we seek to bring new medicines to patients in need.” Dr. Berelowitz currently serves as a biopharmaceuticals consultant, and is a member of several Boards of Directors or Scientific Advisory Boards, including, Oramed Pharmaceuticals, Recro Pharma, Inc. and DIR Technologies. Additionally, Dr. Berelowitz has served on the Board of Directors of the American Diabetes Association, the Endocrine Fellows Foundation, the Clinical Initiatives Committee of the Endocrine Society, Metacure, Ltd., Haptocure, Ltd., and has chaired the Task Force on Research of the New York State Council on Diabetes. He has served as a member of the Industry Education Steering Committee of the American Association of Clinical Endocrinologists (AACE) as well as serving on several editorial boards, including the Journal of Clinical Endocrinology and Metabolism, Endocrinology, Reviews in Endocrine and Metabolic Disorders and Clinical Diabetes. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes and metabolic disorders. A native of Zimbabwe, Dr. Berelowitz completed his medical degree, residency training in Pathology, Nuclear Medicine and Internal Medicine and fellowship training in Endocrinology and Metabolism at the University of Cape Town. Kamada Ltd. is focused on the development and commercialization of its plasma-derived protein therapeutics for immunomodulation in orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxalta. In addition to Glassia, Kamada has a product line of nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed pivotal Phase 2/3 clinical trials in Europe and entered Phase 2 clinical trials in the U.S. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties. This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.


The global insulin market is expected to reach USD 47.54 billion by 2020, according to a new study by Grand View Research, Inc. Growing global prevalence of type I and type II diabetes and the presence of high unmet needs in emerging markets such as India and China are expected to be two of the most significant growth drivers of this market. Moreover, increasing incidence rates of lifestyle induced diseases such as obesity and growing global geriatric population base are expected to serve the global insulin market as drivers. Browse full research report with TOC on "Insulin Market Analysis By Product (Fast Acting, Short Acting, Intermediate Acting, Pre-Mix and Long Acting), By Segments (Insulin Analogs And Human Recombinant Insulin), By Application (Type I and Type II Diabetes) And Segment Forecasts To 2020" at: http://www.grandviewresearch.com/industry-analysis/insulin-market The global intermediate and long acting insulin segments were two of the largest markets in 2013 and together accounted for over 45% of the overall revenue. Higher efficacy exhibited by these segments in terms of insulin peak time is one of the major factors accounting for their large market shares. Further key findings from the study suggest: Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals For the purpose of this study, Grand View Research has segmented the Insulin Market on the basis of product, segment (on the basis of source), application and region: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


The global insulin market is expected to reach USD 47.54 billion by 2020, according to a new study by Grand View Research, Inc. Growing global prevalence of type I and type II diabetes and the presence of high unmet needs in emerging markets such as India and China are expected to be two of the most significant growth drivers of this market. Moreover, increasing incidence rates of lifestyle induced diseases such as obesity and growing global geriatric population base are expected to serve the global insulin market as drivers. Browse full research report with TOC on "Insulin Market Analysis By Product (Fast Acting, Short Acting, Intermediate Acting, Pre-Mix and Long Acting), By Segments (Insulin Analogs And Human Recombinant Insulin), By Application (Type I and Type II Diabetes) And Segment Forecasts To 2020" at: http://www.grandviewresearch.com/industry-analysis/insulin-market The global intermediate and long acting insulin segments were two of the largest markets in 2013 and together accounted for over 45% of the overall revenue. Higher efficacy exhibited by these segments in terms of insulin peak time is one of the major factors accounting for their large market shares. Further key findings from the study suggest: Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals For the purpose of this study, Grand View Research has segmented the Insulin Market on the basis of product, segment (on the basis of source), application and region: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


News Article | August 4, 2015
Site: www.businesswire.com

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announces that the Company has appointed Michael Berelowitz, M.D. to its Board of Directors. With Dr. Berelowitz’ appointment, Kamada’s Board will have ten directors. Dr. Berelowitz brings over 40 years of clinical development and academic research experience, including 15 years of pharmaceutical development experience with Pfizer, Inc. While at Pfizer, Dr. Berelowitz was Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit. He held various other roles at Pfizer, beginning as a Medical Director in the Diabetes Clinical Research team and then assuming positions of increasing responsibility. Prior to that, Dr. Berelowitz spent a number of years in academia and has held appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at StonyBrook and, most recently, Mount Sinai School of Medicine. “It is with great pleasure that we welcome Dr. Berelowitz to our Board. His wide-ranging background, considerable industry experience, and deep insight into successful commercialization and clinical strategies will be extremely valuable to Kamada as we advance and expand our robust clinical development programs for our immunomodulatory plasma-derived protein therapeutics,” stated David Tsur, co-founder and Deputy Chairman of the Board of Kamada. “Specifically, Dr. Berelowitz’ extensive knowledge of the diabetes landscape will be a great asset for Kamada as we advance our AAT to treat type-1 diabetes.” In accepting this appointment, Dr. Berelowitz stated, “I am excited to join Kamada at this important stage in its development. I believe that Kamada’s AAT has considerable potential to modulate or to prevent immune reactions, which could translate to broad therapeutic potential. I am particularly excited about the opportunity for Kamada’s AAT as a treatment for newly-diagnosed type-1 diabetes as it may be able to preserve beta cells, which could slow disease progression, improve metabolic control, and most importantly, reduce the complications of this debilitating disease. I look forward to working with my fellow Kamada Board members and the management team to help the Company achieve its strategic objectives, as we seek to bring new medicines to patients in need.” Dr. Berelowitz currently serves as a biopharmaceuticals consultant, and is a member of several Boards of Directors or Scientific Advisory Boards, including, Oramed Pharmaceuticals, Recro Pharma, Inc. and DIR Technologies. Additionally, Dr. Berelowitz has served on the Board of Directors of the American Diabetes Association, the Endocrine Fellows Foundation, the Clinical Initiatives Committee of the Endocrine Society, Metacure, Ltd., Haptocure, Ltd., and has chaired the Task Force on Research of the New York State Council on Diabetes. He has served as a member of the Industry Education Steering Committee of the American Association of Clinical Endocrinologists (AACE) as well as serving on several editorial boards, including the Journal of Clinical Endocrinology and Metabolism, Endocrinology, Reviews in Endocrine and Metabolic Disorders and Clinical Diabetes. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes and metabolic disorders. A native of Zimbabwe, Dr. Berelowitz completed his medical degree, residency training in Pathology, Nuclear Medicine and Internal Medicine and fellowship training in Endocrinology and Metabolism at the University of Cape Town. Kamada Ltd. is focused on the development and commercialization of its plasma-derived protein therapeutics for immunomodulation in orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxalta. In addition to Glassia, Kamada has a product line of nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed pivotal Phase 2/3 clinical trials in Europe and entered Phase 2 clinical trials in the U.S. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties. This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Loading Oramed Pharmaceuticals collaborators
Loading Oramed Pharmaceuticals collaborators